263 related articles for article (PubMed ID: 28477011)
1. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
2. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
[TBL] [Abstract][Full Text] [Related]
3. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia.
Kim HJ; Choi EJ; Sohn HJ; Park SH; Min WS; Kim TG
Eur J Haematol; 2013 Nov; 91(5):411-22. PubMed ID: 23826993
[TBL] [Abstract][Full Text] [Related]
6. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
[TBL] [Abstract][Full Text] [Related]
7. PRAME peptide-specific CD8
Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analyses of leukemia-associated antigen-specific CD8
Rücker-Braun E; Link CS; Schmiedgen M; Tunger A; Vizjak P; Teipel R; Wehner R; Kühn D; Fuchs YF; Oelschlägel U; Germeroth L; Schmitz M; Bornhäuser M; Schetelig J; Heidenreich F
Exp Hematol; 2016 Nov; 44(11):1024-1033.e1. PubMed ID: 27473564
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
11. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
12. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
13. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
14. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia.
Sundarasetty BS; Singh VK; Salguero G; Geffers R; Rickmann M; Macke L; Borchers S; Figueiredo C; Schambach A; Gullberg U; Provasi E; Bonini C; Ganser A; Woelfel T; Stripecke R
Hum Gene Ther; 2013 Feb; 24(2):220-37. PubMed ID: 23311414
[TBL] [Abstract][Full Text] [Related]
15. Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML.
Kim YJ; Cho SG; Lee S; Kim MS; Kim EK; Cho BS; Sohn HJ; Choi HB; Eom KS; Min CK; Kim HJ; Kim YG; Kim DW; Lee JW; Min WS; Kim CC; Kim TG
Bone Marrow Transplant; 2010 Mar; 45(3):597-9. PubMed ID: 19684628
[No Abstract] [Full Text] [Related]
16. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
17. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
Maslak PG; Dao T; Krug LM; Chanel S; Korontsvit T; Zakhaleva V; Zhang R; Wolchok JD; Yuan J; Pinilla-Ibarz J; Berman E; Weiss M; Jurcic J; Frattini MG; Scheinberg DA
Blood; 2010 Jul; 116(2):171-9. PubMed ID: 20400682
[TBL] [Abstract][Full Text] [Related]
19. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
